Techcyte's digital diagnostics platform applies the latest in convolutional neural networks to assist ARUP's staff in delivering fast and accurate results to doctors and patients.
The platform supports a range of whole slide scanners as well as multiple tests, such as blood differential, cervical cytology, fine needle aspiration, ova and parasites (fecal), urinalysis, and bacteriology.
The collaboration between ARUP and Techcyte will significantly accelerate the number of new test algorithms available to the lab diagnostic market.
ARUP's vast expertise and access to rare samples combined with Techcyte's data-pipeline and machine-learning experts will produce high-quality algorithms that can be developed quickly and then introduced into the market following thorough testing.
Medical labs, hardware manufacturers, hospitals, and clinics will all benefit from Techcyte's solutions. In 2019, Techcyte will deliver solutions for blood analysis, fecal ova and parasites, cervical cytology and bacteriology. Additional tests will be announced when they are ready for market use.
Headquartered in Orem, Utah, Techcyte, Inc. was founded in 2013 as a technology transfer from the University of Utah with a mission to lower healthcare costs through artificial intelligence.
Techcyte uses the power of deep machine learning to perform image analysis of whole slide images. Image analysis is required for widespread adoption of digital pathology in research, pharma, human, air quality and veterinary diagnostic testing.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development.
A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique lab tests, with accompanying consultative support, to enhance their abilities to provide laboratory services.
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS